Background The overall survival rate for pediatric osteosarcoma (OS), neuroblastoma (NB) and glioblastoma (GBM) in children with relapsed/refractory and metastatic disease remains dismal. Our group has successfully expanded peripheral blood… Click to show full abstract
Background The overall survival rate for pediatric osteosarcoma (OS), neuroblastoma (NB) and glioblastoma (GBM) in children with relapsed/refractory and metastatic disease remains dismal. Our group has successfully expanded peripheral blood Natural Killer cells (exPBNK) with irradiated feeder cells (Chu/Cairo, et al, Can Imm Res 2015). ALT-803 (N-803) is a superagonist of an IL-15 variant bound to an IL-15RαSu-Fc fusion with enhanced IL-15 biological activity (Zhu et al. 2009 J Immunol). Tim-3 was found expressed on active NK cells and its expression in cancer patientsO NK cells correlated with disease stage and prognosis. Objective To determine if the combination of N-803 and TIM-3 blockage significantly enhances exPBNK cell cytotoxicity against OS, GBM and NB Method PBMCs were expanded with lethally irradiated K562-mbIL21-41BBL cells. CD56+CD3− exPBNK cells were isolated using Miltenyi NK cell isolation kit. N-803 was generously provided by Altor BioScience. ExPBNK were cultured with 3.5ng/ml N-803 and 10 or 20ug/ml anti-TIM-3 antibody. NK proliferation, NK receptors expression and cytotoxicity were examined (Chu/Cairo, oncoimmunology, 2017). Results N-803 increased NK activating receptorO expression: NKG2D, NKp30, NKp44, and NKp46. N-803 significantly enhanced exPBNK in vitro cytotoxicity against OS, NB and GBM (p Conclusions The combination of N-803 and anti-Tim-3 blockage significantly enhanced exPBNK in-vitro cytotoxicity against OS, NB and GBM cells. In-vivo effects of the combination are under investigation.
               
Click one of the above tabs to view related content.